Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical science"
DOI: 10.1042/cs20200331
Abstract: Immunotherapies have greatly expanded the armamentarium of cancer-directed therapies in the past decade, allowing the immune system to recognize and fight cancer. Immune checkpoint inhibitors (ICIs), in particular, have revolutionized cancer treatment and have demonstrated… read more here.
Keywords: immune checkpoint; toxicities associated; cancer; cardiovascular toxicities ... See more keywords
Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2023.2182284
Abstract: BACKGROUND Anaplastic lymphoma kinases (ALK) tyrosine kinase inhibitors (TKIs) are targeted therapies used in advanced ALK-positive non-small cell lung cancers (NSCLC) which showed excellent efficacy and safety. However, ALK TKIs-associated cardiovascular toxicities [cardiac disorders, venous… read more here.
Keywords: meta analysis; toxicities associated; cardiovascular toxicities; alk tkis ... See more keywords
Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2023.2181160
Abstract: ABSTRACT Introduction Linezolid can cause serious adverse effects including thrombocytopenia and anemia. Here, we focus specifically on linezolid-related hematological toxicity in adult patients requiring prolonged drug treatment. Areas covered We review the available evidence on… read more here.
Keywords: hematological toxicities; linezolid therapy; associated linezolid; thrombocytopenia ... See more keywords
Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13707
Abstract: Immune checkpoint inhibitors (ICIs) have significantly improved clinical outcomes for a wide range of cancers but can also lead to cardiovascular toxicities. This study was to scientifically and systematically explore the association between cardiovascular toxicities… read more here.
Keywords: checkpoint inhibitors; immune checkpoint; associated immune; toxicities associated ... See more keywords